keyword
MENU ▼
Read by QxMD icon Read
search

Telbivudine

keyword
https://www.readbyqxmd.com/read/28591041/relationship-of-treg-th17-balance-with-hbeag-change-in-hbeag-positive-chronic-hepatitis-b-patients-receiving-telbivudine-antiviral-treatment-a-longitudinal-observational-study
#1
Xiaoling Yang, Jia Li, Jie Liu, Min Gao, Li Zhou, Wei Lu
Telbivudine (LdT) is an orally L-nucleoside with potent and specific antihepatitis B virus (HBV) activity. The higher rate of hepatitis B e antigen (HBeAg) seroconversion of LdT treatment than other anti-HBV agents suggests a potential immunomodulatory effect. The aim of the study was to investigate the changes of regulatory T cell (Treg)/interleukin (IL)-17-producing CD4+T helper (Th17) balance during LdT treatment and to discuss the relationship of Treg/Th17 balance with HBeAg change in HBeAg-positive chronic hepatitis B (CHB) patients receiving LdT antiviral treatment...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28562554/effectiveness-of-entecavir-or-telbivudine-therapy-in-patients-with-chronic-hepatitis-b-virus-infection-pre-treated-with-interferon-compared-with-de-novo-therapy-with-entecavir-and-telbivudine
#2
Shaohang Cai, Jiawei Cao, Tao Yu, Muye Xia, Jie Peng
Little is known about the optimal treatment following the initial failure of interferon therapy and the potential different efficacy with de novo therapy with entecavir (ETV) or telbivudine (LDT) and following the interferon therapy failure.ETV or LDT therapy following the interferon therapy failure was compared with that of de novo therapy with ETV or LDT in patients with chronic hepatitis B virus (HBV) infection. Treatment parameters included virological response, hepatitis B e antigen (HBeAg) seroconversion, and alanine aminotransferase (ALT) normalization...
June 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28551372/clinical-course-and-perinatal-transmission-of-chronic-hepatitis-b-during-pregnancy-in-a-real-life-setting-a-prospective-cohort-study
#3
Zhi-Xian Chen, Gui-Fang Gu, Zhao-Lian Bian, Wei-Hua Cai, Yi Shen, Yan-Li Hao, Sheng Zhang, Jian-Guo Shao, Gang Qin
OBJECTIVE: To determine the clinical course and perinatal transmission of chronic hepatitis B during pregnancy in a real life setting. METHODS: A total of 221 singleton pregnant women with detectable HBV-DNA levels (≥10(3) copies/mL) were enrolled during January 2011 to June 2015. Forty-three high viraemic patients (≥ 10(6) copies/mL) received telbivudine in the 2nd or 3rd trimester according to their intention, while 89 high viraemic and 79 low viraemic (≥10(3) and <10(6) copies/mL) patients were the control cohorts...
May 24, 2017: Journal of Infection
https://www.readbyqxmd.com/read/28539842/a-review-of-antiviral-use-for-the-treatment-of-chronic-hepatitis-b-virus-infection-in-pregnant-women
#4
Ariel Jaffe, Robert S Brown
Mother-to-child transmission (MTCT) of hepatitis B virus (HBV) remains high even with the proper use of active-passive immunoprophylaxis in newborns. Mothers with significant viremia are at a much higher risk of MTCT; therefore, treatments aimed at lowering HBV DNA levels during pregnancy may ultimately decrease global disease burden. The exact threshold for treatment remains controversial; however, most studies have accepted levels greater than 2 × 5 log10 IU/mL as significant viremia. We reviewed the most recent literature on antiviral efficacy, maternal and fetal safety, and viral resistance patterns when used for short-duration therapy in pregnancy...
March 2017: Gastroenterology & Hepatology
https://www.readbyqxmd.com/read/28522916/early-hepatitis-b-viral-dna-clearance-predicts-treatment-response-at-week-96
#5
Xiao-Yu Fu, De-Ming Tan, Cui-Mei Liu, Bin Gu, Li-Hua Hu, Zhong-Tian Peng, Bin Chen, Yuan-Lin Xie, Huan-Yu Gong, Xiao-Xuan Hu, Lian-Hui Yao, Xiao-Ping Xu, Zheng-Yuan Fu, Lang-Qiu He, Si-Hai Li, Yun-Zhu Long, De-Hui Li, Ji-Long Gu, Shi-Fang Peng
AIM: To investigate whether hepatitis viral DNA load at 24 wk of treatment predicts response at 96 wk in patients with chronic hepatitis B. METHODS: A total of 172 hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B patients who received initial treatment at 16 tertiary hospitals in Hunan Province, China were enrolled in this study. All patients received conventional doses of lamivudine and adefovir dipivoxil, telbivudine, entecavir dispersible tablets, or entecavir tablets for 96 wk...
April 28, 2017: World Journal of Gastroenterology: WJG
https://www.readbyqxmd.com/read/28478758/-rhabdomyolysis-associated-with-telbivudin-therapy-report-of-a-case
#6
Almudena Mancebo González, María José Peñalver Jara, Laura Menéndez Naranjo, Ana Patricia Navarro Egea
No abstract text is available yet for this article.
May 1, 2017: Farmacia Hospitalaria
https://www.readbyqxmd.com/read/28445403/detection-of-hepatitis-b-virus-m204i-mutation-by-quantum-dot-labeled-dna-probe
#7
Cheng Zhang, Yiping Chen, Xinmiao Liang, Guanhua Zhang, Hong Ma, Leng Nie, Yu Wang
Quantum dots (QDs) are semiconductor nanoparticles with a diameter of less than 10 nm, which have been widely used as fluorescent probes in biochemical analysis and vivo imaging because of their excellent optical properties. Sensitive and convenient detection of hepatitis B virus (HBV) gene mutations is important in clinical diagnosis. Therefore, we developed a sensitive, low-cost and convenient QDs-mediated fluorescent method for the detection of HBV gene mutations in real serum samples from chronic hepatitis B (CHB) patients who had received lamivudine or telbivudine antiviral therapy...
April 26, 2017: Sensors
https://www.readbyqxmd.com/read/28434087/hepatitis-b-during-pregnancy-in-endemic-areas-screening-treatment-and-prevention-of-mother-to-child-transmission
#8
REVIEW
Naichaya Chamroonkul, Teerha Piratvisuth
The proper management of pregnant women infected with hepatitis B virus (HBV) is necessary to prevent maternal and fetal morbidity and mortality and to protect the baby from HBV infection. In the majority of cases, vertical transmission can be prevented with a universal screening program, HBV vaccine immunoprophylaxis, and administration of hepatitis B immunoglobulin (HBIg) for babies born to mothers with HBV. However, in mothers with a high viral load (>200,000 or >1,000,000 IU/ml, depending on the guideline), the chance of immunoprophylaxis failure remains high...
June 2017: Paediatric Drugs
https://www.readbyqxmd.com/read/28422442/effect-of-hepatitis-b-virus-subgenotype-on-antiviral-response-in-nucleoside-treated-hepatitis-b-envelope-antigen-positive-patients
#9
Sheng Shen, Xieer Liang, Kamal Hamed, Yasuhito Tanaka, Katsumi Omagari, Rong Fan, Qing Xie, Deming Tan, Bin Zhou, Ji-Dong Jia, Jinlin Hou, Jian Sun
AIM: Previous studies have reported that hepatitis B virus (HBV) genotype is not a predictor of treatment response with nucleos(t)ide analog therapy. However, the impact of subgenotype on treatment response is unknown. The aim of this study is to identify the effect of HBV subgenotype on treatment response. METHODS: In this retrospective study, the derivation dataset comprised patients from the EFFORT study (NCT00962533) telbivudine monotherapy group; patients infected with genotypes B or C from the GLOBE (NCT00057265) and 015 (NCT00131742) studies formed the validation dataset...
April 19, 2017: Hepatology Research: the Official Journal of the Japan Society of Hepatology
https://www.readbyqxmd.com/read/28407735/telbivudine-treatment-started-in-early-and-middle-pregnancy-completely-blocks-hbv-vertical-transmission
#10
Weihui Sun, Shangfei Zhao, Lei Ma, Anhua Hao, Bo Zhao, Lin Zhou, Fengzhu Li, Mingquan Song
BACKGROUND: To evaluate the efficacy and safety of treating HBV-positive mothers with telbivudine in early and middle pregnancy to prevent mother-to-infant HBV transmission. METHODS: The subject population comprised pregnant women with chronic hepatitis B (CHB; n = 188) from January 2013 to June 2015, with HBV DNA ≥1.0 × 10(7)copies/mL and increased alanine aminotransferase levels. Groups A (n = 62) and B (n = 61) were treated with telbivudine starting at 12 weeks or 20-28 weeks after gestation, respectively...
April 13, 2017: BMC Gastroenterology
https://www.readbyqxmd.com/read/28386259/elevated-expression-of-chemokine-cxcl13-in-chronic-hepatitis-b-patients-links-to-immune-control-during-antiviral-therapy
#11
Chao Liu, Xuan Huang, Melanie Werner, Ruth Broering, Jun Ge, Yongyin Li, Baolin Liao, Jian Sun, Jie Peng, Mengji Lu, Jinlin Hou, Xiaoyong Zhang
C-X-C-chemokine ligand 13 (CXCL13), the ligand for C-X-C chemokine receptor type 5 (CXCR5), is a major regulator of B-cell trafficking and plays an integral role in age-dependent clearance of hepatitis B virus (HBV) in the mouse model. However, the expression and function of CXCL13 in patients with chronic hepatitis B (CHB) remain unknown. By use of liver cell subpopulations isolated from CHB patients, we found that CXCL13 mRNA was abundantly expressed in Kupffer cells (KCs), but not in primary hepatocytes, liver sinusoidal endothelial cells, and hepatic stellate cells...
2017: Frontiers in Immunology
https://www.readbyqxmd.com/read/28373116/telbivudine-attenuates-gentamicin-induced-kidney-injury-in-rats
#12
Cigdem Kader, Mustafa Sunbul, Yavuz Kursad Das, Murat Yarim, Abdulkerim Bedir, Efe Karaca, Mehmet Celikbilek, Resat Ozaras
Nephrotoxicity has been associated with nucleos(t)ide analogues other than telbivudine (LdT). This study investigated the potential effects of LdT and lamivudine (LAM) on renal function in an experimental rat model of gentamicin-induced acute nephrotoxicity. A total of 28 healthy Wistar albino rats were randomly divided into four experimental groups: negative control; positive control (PC); LdT; and LAM. Nephrotoxicity was induced by gentamicin in the LdT, LAM and PC groups. LdT and LAM were administered to two groups for 6 weeks starting on the ninth day...
May 2017: International Journal of Antimicrobial Agents
https://www.readbyqxmd.com/read/28351603/predictors-of-hbeag-seroconversion-after-long-term-nucleos-t-ide-analogues-treatment-for-chronic-hepatitis-b-a-multicenter-study-in-real-clinical-setting
#13
Weiyan Yu, Yadong Wang, Chuan Shen, Ru Ji, Li Zhang, Xin Zhao, Miao Su, Ying Zhang, Wenyan He, Jianguo Cao, Yanshuang Hao, Shengpeng Chen, Caiyan Zhao
AIMS: To evaluate the HBeAg seroconversion rate in real clinical setting and explore its predictors in long-term nucleos(t)ide analogues (NAs) treatment for chronic hepatitis B (CHB). METHODS: 251 patients were recruited from January 2001 to September 2009 in four hospitals in Hebei province, China, for this retrospective study. Clinical and laboratory data before and after treatment with lamivudine (LAM, 100mg daily), adefovir (ADV, 10mg daily), telbivudine (LDT, 600mg daily), entecavir (ETV, 0...
March 27, 2017: Brazilian Journal of Infectious Diseases
https://www.readbyqxmd.com/read/28345181/hbsag-kinetics-during-treatment-with-nucleos-t-ides-analogues-in-patients-with-hbeag-negative-chronic-hepatitis-b
#14
Athanasia Striki, Spilios Manolakopoulos, Melanie Deutsch, Anastasia Kourikou, George Kontos, Hariklia Kranidioti, Emilia Hadziyannis, George Papatheodoridis
BACKGROUND/AIMS: Serum HBsAg levels might be used as predictor of virological breakthrough or of sustained off-treatment virological response in HBeAg-negative chronic hepatitis B (CHB) patients. We evaluated the changes of HBsAg in those patients under nucleos(t)ide analogue(s) [NA(s)] therapy for ≥12 months. METHODS: We included 99 HBeAg-negative CHB patients treated with low-genetic barrier NA(s) for a mean of 66 months (lamivudine: 66, adefovir: 6, lamivudine plus adefovir: 11, telbivudine: 16) and 86 HBeAg-negative CHB patients under entecavir or tenofovir for a mean of 30 months as the comparison group...
March 26, 2017: Liver International: Official Journal of the International Association for the Study of the Liver
https://www.readbyqxmd.com/read/28332360/entecavir-to-telbivudine-switch-therapy-in-entecavir-treated-patients-with-undetectable-hepatitis-b-viral-dna
#15
RANDOMIZED CONTROLLED TRIAL
Dong Hyun Kim, Jong Won Choi, Jeong Hun Seo, Yong Suk Cho, Sun Young Won, Byung Kyu Park, Han Ho Jeon, Sang Yun Shin, Chun Kyon Lee
PURPOSE: This study examined 2-year outcome of consecutive therapy using entecavir (ETV) followed by telbivudine (LdT) in subjects with undetectable hepatitis B virus (HBV) DNA level and normal alanine aminotransferase level after the initial 6 months of ETV treatment. MATERIALS AND METHODS: Sixty subjects were randomized to continue with ETV or switch to LdT. Significant difference in baseline characteristics was not found between the two groups. Persistent HBV DNA level of 20-60 IU/mL in three consecutive samples collected three months apart or singly measured HBV DNA level of >60 IU/mL was defined as virological rebound...
May 2017: Yonsei Medical Journal
https://www.readbyqxmd.com/read/28317397/nucleos-t-ide-analogues-for-preventing-hbv-reactivation-in-immunosuppressed-patients-with-hematological-malignancies-a-network-meta-analysis
#16
Min-Yue Zhang, Gui-Qi Zhu, Ji-Na Zheng, Zhang Cheng, Sven Van Poucke, Ke-Qing Shi, Hong-Hui Huang, Fang-Yuan Chen, Ming-Hua Zheng
BACKGROUND: We aimed to evaluate the efficacy of five oral nucleos(t)ide analogues (NAs), including lamivudine, entecavir, adefovir, telbivudine and tenofovir, for the prevention of hepatitis B virus (HBV) reactivation and HBV-related complications in chronic hepatitis B virus (CHB) infected patients with hematological malignancies receiving chemotherapy or hematopoietic stem cell transplantation (HSCT) by network meta-analysis. METHODS: The search identified 28 articles involving 5 different prophylactic regimens covering 1478 participants...
March 29, 2017: Expert Review of Anti-infective Therapy
https://www.readbyqxmd.com/read/28316253/predominance-of-hepatitis-b-virus-genotype-a-among-treated-hiv-infected-patients-experiencing-high-hepatitis-b-virus-drug-resistance-in-nairobi-kenya
#17
Sepha Nyatichi Mabeya, Caroline Ngugi, Raphael Wekesa Lihana, Samoel Ashimosi Khamadi, Anthony Kebira Nyamache
Hepatitis B virus (HBV)-HIV coinfections are becoming common with information on HBV genetic diversity and drug resistance still remaining elusive. To evaluate the HBV genetic diversity and drug resistance-associated mutations among drug-experienced HIV patients, the genetic analysis of the partial HBV-pol-reverse trancriptase gene was successfully sequenced from 13 samples. Analysis of the sequences showed that all (11) the sequences belonged to genotype A. Nucleos(t)ide drug resistance mutations were found in 6 patients...
April 18, 2017: AIDS Research and Human Retroviruses
https://www.readbyqxmd.com/read/28270871/antiviral-therapy-in-chronic-hepatitis-b-with-mild-acute-exacerbation
#18
Su Lin, Qiaoxia Ye, Mingfang Wang, Yinlian Wu, Zhiyuan Weng, Yueyong Zhu
BACKGROUND: The aim of this study was to assess the efficacy and safety of peginterferon α-2a (pegIFN) and nucleos(t)ide analogues (NA) treatments in patients with hepatitis B envelope antigen (HBeAg)-positive chronic hepatitis B (CHB) with mild acute exacerbation (AE). METHODS: Treatment-naive HBeAg-positive CHB patients with AE who received pegIFN or NA (entecavir (ETV) or telbivudine (LDT)) therapies were retrospectively selected. The HBeAg seroconversion rate, hepatitis B surface antigen (HBsAg) loss rate and the cost-effectiveness of different treatments were compared...
February 2017: Gastroenterology Research
https://www.readbyqxmd.com/read/28261380/adverse-effects-of-oral-antiviral-therapy-in-chronic-hepatitis-b
#19
REVIEW
Bircan Kayaaslan, Rahmet Guner
Oral nucleoside/nucleotide analogues (NAs) are currently the backbone of chronic hepatitis B (CHB) infection treatment. They are generally well-tolerated by patients and safe to use. To date, a significant number of patients have been treated with NAs. Safety data has accumulated over the years. The aim of this article is to review and update the adverse effects of oral NAs. NAs can cause class adverse effects (i.e., myopathy, neuropathy, lactic acidosis) and dissimilar adverse effects. All NAs carry a "Black Box" warning because of the potential risk for mitochondrial dysfunction...
February 18, 2017: World Journal of Hepatology
https://www.readbyqxmd.com/read/28231660/-effect-of-telbivudine-on-infants-born-to-hbsag-positive-mothers-with-non-hypo-response-to-hepatitis-b-vaccine-during-their-second-and-third-trimesters-of-pregnancy
#20
X X Xu, B Wang, X F Wang, H X Wen, F Zhang, Z Q Yang, H Y Hao, T Wang, X H Shi, Z D Fu, B Wang, S P Wang
Objective: To explore the effect of telbivudine treatment in a prevention program on infants born to HBsAg-positive mothers with non-/hypo-responsiveness to hepatitis B vaccine. Methods: A retrospective cohort study with a total of 321 HBsAg-positive pregnant women and their infants enrolled, was conducted. The mothers were recruited from the Third People' s Hospital of Taiyuan, from July 2011 to January 2013. According to the situation of telbivudine intake in second and third trimesters of pregnancy, the participants were divided into two groups: with telbivudine-treated or as control...
February 10, 2017: Zhonghua Liu Xing Bing Xue za Zhi, Zhonghua Liuxingbingxue Zazhi
keyword
keyword
2108
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"